CD4 and mitochondrial DNA depletion syndrome 4a: Conclusions: The observed high agreement between VISITECT and flow cytometry results demonstrates that VISITECT can correctly identify patients with AHD and has the potential to improve access to CD4+ testing and linkage to care.